What is Trovagene (Now Cardiff Oncology)'s contact information?

Trovagene (Now Cardiff Oncology)'s contact information: +18589527570.

How many employees does Trovagene (Now Cardiff Oncology) have?

Trovagene (Now Cardiff Oncology) has 32 employees.

What industry does Trovagene (Now Cardiff Oncology) belong to?

Trovagene (Now Cardiff Oncology) is in the industry of: Research.

What are Trovagene (Now Cardiff Oncology)'s official social media profiles?

Trovagene (Now Cardiff Oncology) Linkedin Page Trovagene (Now Cardiff Oncology) Twitter Page

What tech stack does Trovagene (Now Cardiff Oncology) use?

Some of the popular technologies that Trovagene (Now Cardiff Oncology) uses are: WordPress, Cloudflare, WordPress.

What are Trovagene (Now Cardiff Oncology)'s office addresses?

Trovagene (Now Cardiff Oncology) has 2 known office addresses: 11055 Flintkote Avenue, San Diego, California, 92121, US 11055 Flintkote Avenue, San Diego, California 92121, Us.

What is Trovagene (Now Cardiff Oncology)'s estimated annual revenue?

Trovagene (Now Cardiff Oncology)'s revenue is $2,526,000

What is Trovagene (Now Cardiff Oncology)'s open headcount?

Trovagene (Now Cardiff Oncology) has no job postings yet.

What is the number of ad campaigns for Trovagene (Now Cardiff Oncology)?

Trovagene (Now Cardiff Oncology) has no advertisements yet.

What is the number of recent news articles about Trovagene (Now Cardiff Oncology)?

Trovagene (Now Cardiff Oncology) has 2 news articles.

Trovagene (Now Cardiff Oncology) - Pubrio Company Profile & Intent

Trovagene (Now Cardiff Oncology)

United States · Research

Research

Cardiff Oncology is a clinical-stage biotechnology company based in San Diego, California. Formerly known as Trovagene, the company rebranded in 2020. Cardiff Oncology specializes in developing precision oncology therapies, focusing on inhibiting Polo-like kinase 1 (PLK1), a key target in cancer treatment. The company's lead product candidate, onvansertib, is a PLK1 inhibitor currently being evaluated in various clinical programs. These include trials for RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer. Cardiff Oncology collaborates with leading healthcare institutions, such as Memorial Sloan Kettering Cancer Center, to advance its clinical trials and address significant unmet medical needs in cancer care.